Search results for Aurobindo Pharma

Pharma Stock in Focus After Board Approves Buyback of Shares Worth ₹800 Cr

Synopsis: The Hyderabad-based pharma giant has given the green light to repurchase shares at ₹1,475 each, a 10% premium over the current market price.  A major Indian pharma giant...

Pharma Stock to Buy Now for 25% Upside Potential; Recommended by Goldman Sachs

Synopsis: Aurobindo Pharma drew brokerage attention after strong Europe-led growth and steady Q4 FY26 performance, with analysts highlighting margin stability and positive medium-t...

Aurobindo Pharma Hits 52-Week High on ₹1,450 Cr Biologics Deal with MSD

Synopsis: Expanding a CMO relationship first disclosed in May 2024, Aurobindo Pharma’s subsidiary TheraNym Biologics has signed an additional product schedule with Merck Sharp &amp...

IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma shares hit 52-week highs; what's next?

Other pharma stocks, including Wockhardt Ltd, Lupin Ltd, Divi's Laboratories Ltd, Zydus Lifesciences Ltd, Torrent Pharmaceuticals Ltd, JB Chemicals & Pharmaceuticals Ltd, Manki...

Aurobindo Pharma share buyback, Muthoot Fin dividend, 2 other corporate actions next week

Aurobindo Pharma’s share buyback and Muthoot Finance’s dividend announcement headline a set of four key corporate actions lined up for the coming week.

Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid drag

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lost Revlimid sales and pricing challenges....

Gland Pharma, Sun Pharmaceutical, Laurus Labs shares zoom up to 16% to hit 52-week highs; here's why

Gland Pharma jumped 15.85 per cent to Rs 2,164.40, while Sun Pharma climbed 1 per cent to Rs 1,896.90. Laurus Labs moved up 0.63 per cent to Rs 1,332.

Orbicular gets USFDA’s tentative nod for generic Semaglutide Injection in partnership with Apotex

The product will be marketed and commercialised in the United States by Apotex Corp., the ANDA applicant

Indian drugmakers look beyond generics as Sun Pharma buys Organon

Sun Pharma to acquire US-based Organon in $11.75bn deal

Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overse...

India’s Sun Pharma to acquire US-listed Organon in $11.8 billion deal

Sun Pharma inks ‘transformatory’ agreement to buy US-based Organon for $11.75 billion

On completion of the deal, the combined entity will have $12.4 billion in revenue, placing Sun among the top 25 global pharma firms

<![CDATA[Pharma M&A Roundup: IMG Pharma Acquires Matsumoto Pharmaceutical, Sun Pharma Acquires Organon ]]>

Sun Pharma puts in place team to integrate Organon global operations

Integration committee to be operational in less than a month, ready to roll out once all approvals come in

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

Pharma Companies Invest In US While India Still Depends On China For APIs

“For decades, India built its reputation as the “pharmacy of the world” by manufacturing low-cost generic medicines that reached millions across Africa, Latin America, and Asia. Bu...

Zydus and Lupin Join Alembic in 180-Day Sprint for $10.5 Billion Dapagliflozin Market

Synopsis: Zydus, Lupin, and Biocon join Alembic in a high-stakes US launch of generic Farxiga, sharing 180-day exclusivity for a blockbuster diabetes drug with $10.5 billion in ann...

Sun Pharma-Organon deal: Outlook is mixed

Acquisition doubles footprint but growth challenges are considerable

Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Divide...

NewsVoirNew Delhi [India], May 15: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial resul...

Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Divide...

NewsVoirNew Delhi [India], May 15: Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial resul...

Pharma stock jumps 9% after signing $11.75 Bil deal to acquire US-based firm

Synopsis:- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co. for $14 per share in an all-cash deal worth $11.75 billion in enterprise val...

US Investments Intended To Take Indian Pharma Up The Value Chain: Interview

This is the first time such huge investments are being made. The Indian pharmaceutical industry has grown from small companies into multinational corporations. Out of the top 20 gl...

AstraZeneca India plans to sell 64-acre Bengaluru site for ₹3,400 crore

AstraZeneca's Indian unit is planning to sell its 64-acre manufacturing facility in North Bengaluru for an estimated ₹3,400 crore. The move is part of a global review of its manufa...